ADX40-Lymphoma

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameADX40-Lymphoma

Drug Alias Namelymphoma vaccine (ADX-40 adjuvant) (Adjuvantix)dual CD40 costimulator/lymphoma antigen vaccine (Adjuvantix)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Antigen > Tumor antigen

Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 agonists

TargetsTumor necrosis factor receptor superfamily member 5

Therapy Area/IndicationsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAdjuvantix Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAdjuvantix Ltd

Active IndicationsN/A

Inactive IndicationsLymphoma

Other Information

ATC CodeN/A